公司资料
OmniAb 股价、新闻与催化剂
- 股票代码:
- OABI
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
4.30 USD (+2.63%)
收盘价
最后更新: 2026年8月20日
380M USD
市值
股价为何变动
As of Aug 20, 2026, OABI closed up 2.63% at $4.30. No new same-company headline was identified in the current news window.
公司概览
业务概览
OmniAb is a biotechnology platform company that monetizes antibody discovery technology through partnerships and licensing. It provides tools and engineered animal platforms to discover therapeutic antibodies.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, OmniAb sits in biotech infrastructure and discovery platforms.
商业模式特征
Revenue depends on partner demand, technology adoption, and the economics of platform licensing rather than direct drug sales.
生物医药行业定位
OmniAb is an enabling antibody-platform name whose value comes from discovery infrastructure and partnership monetization.
未来催化剂
- OmniAb’s catalysts are partner-program milestones, royalty or milestone revenue, and whether the antibody-discovery platform keeps producing value across partners. The market will care about utilization and downstream optionality more than a single headline.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。